ema prac naion semaglutide very rare side effect 2025 Meeting highlights from the Pharmacovigilance Risk Assessment Committee ( PRAC) 2-5 June EMA safety committee to review

During these clinical trials, researchers observed substantial weight loss in participants, which paved the way for a second approval

It was approved by the U.S

The United States is the world's dominant GLP-1 receptor agonist market by an enormous margin, with over 45% of global GLP-1 revenues generated domestically despite representing less than 5% of the world's diabetes and obesity patient population

Research shows that weight regain after discontinuing semaglutide is common, often occurring within three to six months

Conclusion Increasing your dose of Semaglutide or Tirzepatide should be a gradual process thats done carefully and based on your individual progress